Half-year report · HY

Period2026-01-01 → 2026-06-30
Filed2026-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥401m2026-01-01 → 2026-06-30Cons.Net sales
Revenue¥579m2025-01-01 → 2025-12-31Cons.Net sales (5-year summary)
Revenue¥251m2025-01-01 → 2025-06-30Cons.Net sales
Operating income−¥954m2026-01-01 → 2026-06-30Cons.Operating income
Operating income−¥1.1bn2025-01-01 → 2025-06-30Cons.Operating income
Ordinary income−¥1.0bn2026-01-01 → 2026-06-30Cons.Ordinary income
Ordinary income−¥2.1bn2025-01-01 → 2025-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.1bn2025-01-01 → 2025-06-30Cons.Ordinary income
Profit before tax−¥1.0bn2026-01-01 → 2026-06-30Cons.Income before income taxes
Profit before tax−¥1.1bn2025-01-01 → 2025-06-30Cons.Income before income taxes
Net income (owners)−¥1.0bn2026-01-01 → 2026-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.2bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.0bn2026-01-01 → 2026-06-30Cons.Profit loss
Net income−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss
Total assets¥1.8bnat 2026-06-30Cons.Assets
Total assets¥1.2bnat 2025-12-31Cons.Assets
Total assets¥1.6bnat 2025-06-30Cons.Total assets (5-year summary)
Total liabilities¥2.2bnat 2026-06-30Cons.Liabilities
Total liabilities¥920mat 2025-12-31Cons.Liabilities
Net assets / equity−¥408mat 2026-06-30Cons.Net assets
Net assets / equity¥309mat 2025-12-31Cons.Net assets
Net assets / equity¥1.4bnat 2025-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.1bnat 2026-06-30Cons.Cash and deposits
Cash and deposits¥517mat 2025-12-31Cons.Cash and deposits
Cash & equivalents¥1.1bnat 2026-06-30Cons.Cash and cash equivalents
Cash & equivalents¥517mat 2025-12-31Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31vCons.Cash and cash equivalents
Operating cash flow−¥915m2026-01-01 → 2026-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.2bn2025-01-01 → 2025-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥995m2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥11m2026-01-01 → 2026-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥25m2025-01-01 → 2025-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥16m2025-01-01 → 2025-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.5bn2026-01-01 → 2026-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥605m2025-01-01 → 2025-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥14m2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-53.132026-01-01 → 2026-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-113.622025-01-01 → 2025-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-55.292025-01-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio-23.9%at 2026-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio25.1%at 2025-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio85.1%at 2025-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
Drug Discovery Businessreportable segmentsegment profit2026-01-01 → 2026-06-30−¥1.0bn
Drug Discovery Support Businessreportable segmentrevenue2026-01-01 → 2026-06-30¥401m
Drug Discovery Support Businessreportable segmentrevenue external2026-01-01 → 2026-06-30¥401m
Drug Discovery Support Businessreportable segmentsegment profit2026-01-01 → 2026-06-30¥67m
Drug Discovery Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥1.0bn
Drug Discovery Support Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥251m
Drug Discovery Support Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥251m
Drug Discovery Support Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥51m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 442
ItemContextValueUnit
Address major shareholdersInterimInstant_No7MajorShareholdersMember
Original text (Japanese)東京都千代田区大手町1丁目9番7号大手町フィナンシャルシテイサウスタワー
Name major shareholdersInterimInstant_No8MajorShareholdersMember
Original text (Japanese)山和証券株式会社
Address major shareholdersInterimInstant_No8MajorShareholdersMember
Original text (Japanese)東京都中央区日本橋兜町1番8号
Name major shareholdersInterimInstant_No9MajorShareholdersMember
Original text (Japanese)鈴木 隆啓
Address major shareholdersInterimInstant_No9MajorShareholdersMember
Original text (Japanese)愛知県名古屋市中区
Name major shareholdersInterimInstant_No10MajorShareholdersMember
Original text (Japanese)株式会社SBI証券
Address major shareholdersInterimInstant_No10MajorShareholdersMember
Original text (Japanese)東京都港区六本木1丁目6番1号
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsInterimInstant_SharesWithNoVotingRightsMember-
Description issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsInterimInstant_SharesWithRestrictedVotingRightsOtherMember-
Description issued shares voting rightsInterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember
Original text (Japanese)自己保有株式
Description issued shares voting rightsInterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember
Original text (Japanese)権利内容に何ら限定のない当社における標準的となる株式
Description issued shares voting rightsInterimInstant_OrdinarySharesSharesLessThanOneUnitMember-
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcInterimInstant_Row1Member
Original text (Japanese)カルナバイオサイエンス株式会社
Address of shareholder treasury shares etcInterimInstant_Row1Member
Original text (Japanese)神戸市中央区港島南町一丁目5番5号
Information about officers (text)FilingDateInstantText · Plus
Regulations in accordance with which consolidated financial statements have been prepared financial informationInterimDurationText · Plus
Type1 semi annual consolidated financial statements financial informationInterimDurationText · Plus
Note on independent audit financial informationInterimDurationText · Plus
Type1 semi annual consolidated balance sheet (text)InterimDurationText · Plus
Type1 semi annual consolidated statement of income (text)InterimDurationText · Plus
Type1 semi annual consolidated statement of comprehensive income (text)InterimDurationText · Plus
Type1 semi annual consolidated statement of cash flows (text)InterimDurationText · Plus
Notes uncertainties of entitys ability to continue as going concern semi annual consolidated financial statements (text)InterimDurationText · Plus
Notes regarding allowances directly deducted from balances of assets (text)InterimInstantText · Plus
Major components of selling general and administrative expenses (text)InterimDurationText · Plus
Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text)InterimDurationText · Plus
Notes when there is significant changes in amounts of equity (text)Prior1InterimDurationText · Plus
Notes when there is significant changes in amounts of equity (text)InterimDurationText · Plus
Notes financial instruments semi annual consolidated financial statements (text)InterimDurationText · Plus
Notes segment information etc type1 semi annual consolidated financial statements (text)InterimDurationText · Plus
Footnotes regarding segment information table (text)Prior1InterimDurationText · Plus
Information about impairment loss of non current assets or goodwill etc for each reportable segment (text)Prior1InterimDurationText · Plus
Footnotes regarding segment information table (text)InterimDurationText · Plus
Information about impairment loss of non current assets or goodwill etc for each reportable segment (text)InterimDurationText · Plus
Notes revenue recognition semi annual consolidated financial statements (text)InterimDurationText · Plus
Notes per share information semi annual consolidated financial statements (text)InterimDurationText · Plus
Notes significant events after reporting period semi annual consolidated financial statements (text)InterimDurationText · Plus
Other information consolidated financial statements etc (text)InterimDurationText · Plus
Information about company which provides guarantee to reporting company (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-12-31pass rounding
balance sheet identityconsolidated 2026-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-12-31pass
statement vs summary · net assetsconsolidated 2026-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2026-01-01/2026-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2026-01-01/2026-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsconsolidated 2026-06-30pass